Loading…
The collaboration has led to significant advancements in ibogaine production.
Psyence Biomedical Ltd. (PBM) and PsyLabs announced on July 31, 2025, a breakthrough in the production of high-purity ibogaine, a key compound in their strategic collaboration. This development marks a significant advancement in their joint efforts to enhance the production process and improve the quality of ibogaine.
The collaboration has resulted in the successful optimization of ibogaine synthesis, leading to higher purity levels and more efficient production methods. This breakthrough is expected to support further research and development initiatives in the field of psychedelic-assisted therapies.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.